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Understanding how the extracellular matrix impacts the
function of cancer stem cells (CSCs) is a significant but
poorly understood problem. We report that breast CSCs
produce a laminin (LM) 511 matrix that promotes self-
renewal and tumor initiation by engaging thea6Bb1 integrin
and activating the Hippo transducer TAZ. Although TAZ is
important for the function of breast CSCs, the mechanism is
unknown. We observed that TAZ regulates the transcription
of the a5 subunit of LM511 and the formation of a LM511
matrix. These data establish a positive feedback loop in-
volving TAZ and LM511 that contributes to stemness in
breast cancer.
Supplemental material is available for this article.
Received October 10, 2014; revised version accepted
November 21, 2014.
Most tumors contain a distinct population of cells with
stem cell characteristics, including the ability to self-
renew and populate new tumors. This population is often
referred to as tumor-initiating or cancer stem cells (CSCs)
(Al-Hajj et al. 2003; Baccelli and Trumpp 2012; Visvader
and Lindeman 2012). CSCs are likely responsible for
tumor recurrence in response to therapy and may con-
tribute to metastasis (Dean et al. 2005; Calcagno et al.
2010; Pinto et al. 2013). For this reason, deciphering the
mechanisms that generate and sustain CSCs is a problem of
paramount importance. This issue has been the focus of
intense investigation in recent years, resulting in consider-
able advancements in the understanding of the nature of
CSCs (Visvader andLindeman2012; Beck andBlanpain 2013;
Kreso and Dick 2014) and the realization that their genesis
and function can be determined by their microenvironment
(Scheel andWeinberg 2012). Given this surge in CSC biology,
it is surprising that the contribution of the extracellular
matrix (ECM) has not been investigated more rigorously.
Although the ECM is presumed to impact the genesis and
function of CSCs (Lane et al. 2014; Wong and Kumar 2014),
much remains to be learned about the nature of this in-
volvement and the mechanisms involved.
The a6b1 integrin is an established marker of breast
and other CSCs (Lathia et al. 2010; Goel and Mercurio
2013; Goel et al. 2013). Recently, however, we discovered
that the a6Bb1 integrin, a specific splice variant of the
a6 cytoplasmic domain, is a determinant of breast CSC
function, a function that cannot be executed by a6Ab1,
the other a6 splice variant (Goel et al. 2014; Seguin et al.
2014). Given that the a6 integrins function primarily as
laminin (LM) receptors (Mercurio 1990), this finding
implies that a6Ab1 and a6Bb1 differ in their response
to LM matrices and that a specific LM functions as the
preferred ligand for a6Bb1 to sustain CSC function. This
hypothesis is consistent with a large body of literature
implicating the LMs in mammary gland biology and
breast cancer (e.g., Streuli et al. 1995; Pouliot and Kusuma
2013). The challenge here is to identify LMs that regulate
a6Bb1 specifically and elucidate the mechanisms by which
the LM/a6Bb1 interaction contributes to the function of
breast CSCs. In pursuit of this problem, we discovered that
LM511 is associated with a6Bb1 and functions as the
preferred ligand for this splice variant. Importantly, we
observed that high LM511 expression and the formation of
a LM511 matrix niche characterize breast CSCs. Our data
also reveal that LM511/a6Bb1 activate the Hippo trans-
ducer TAZ, which has been implicated in the function of
breast CSCs (Cordenonsi et al. 2011), providing a novel
mechanism for LM regulation of CSC function. Unexpect-
edly, we discovered that the a5 subunit of LM511 is a TAZ
target gene and that TAZ regulates the formation of a
LM511 matrix, establishing one mechanism for how
TAZ contributes to CSC function.
Results and Discussion
Breast CSCs produce a LM511 matrix that functions
as the ligand for the a6Bb1 integrin to promote
self-renewal and tumor initiation
The goal of this study was to identify the a6Bb1 ligand
that enables this integrin splice variant to promote self-
renewal and initiate new tumors and determine the
mechanisms involved. We used two model systems
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initially to achieve this goal. The CD44+/CD24 pop-
ulation isolated from Src-transformed MCF10A cells
(Iliopoulos et al. 2011) consists of distinct epithelial (EPTH)
and mesenchymal (MES) populations that differ in the
relative expression of the a6A and a6B splice variants and
stem cell properties (Goel et al. 2014). Specifically, the MES
population is enriched in a6Bb1 expression and exhibits
self-renewal and tumor-initiating ability compared with
the EPTH population, which is enriched
for a6A integrin expression. We also engi-
neered SUM1315 cells to express either
the a6Ab1 or a6Bb1 splice variants at
equivalent levels of surface expression
and demonstrated that a6Bb1-expressing
cells exhibit CSC properties in compari-
son with a6Ab1-expressing cells (Goel
et al. 2014). The gene expression profiles
of the EPTH and MES populations were
compared by RNA sequencing (RNA-seq)
analysis (Supplemental Table S1). The
data obtained revealed distinct differences
in the expression of specific LM subunits
between these populations, which we
confirmed by real-time quantitative PCR
(qPCR). Specifically, the MES population
and the a6Bb1-expressing SUM1315 cells
exhibited a significant increase in the
mRNA expression of the LMa5 and
LMb1 subunits and a concomitant de-
crease in the LMa3, LMb2, LMb3, and
LMg2 subunits (Fig. 1A). These results
were corroborated by immunoblotting
(Fig. 1B).
The LMa5 subunit is a component
of LM511 and LM521 (Aumailley et al.
2005; Miner 2008). The fact that LMb2
expression is repressed in the MES and
a6Bb1/SUM1315 cells infers that LM511
correlates with a6Bb1 expression and
stem cell properties and that it appears
to be the preferred ligand for a6Bb1. To
assess this hypothesis, we assayed adhe-
sion to LM511, LM111, fibronectin (FN),
and collagen I (COL 1). Indeed, the MES
population and the a6Bb1/SUM1315
cells adhered better to LM511 than to
the other matrix proteins (Fig. 1C). Also,
the MES and a6Bb1/SUM1315 cells
adhered significantly better to LM511
than the EPTH and a6Ab1/SUM1315
cells (Fig. 1C). Titration of matrix pro-
tein concentration revealed that a6Bb1-
expressing cells adhered much more
avidly to LM511 than to either LM111
or FN (Fig. 1D, left; Supplemental Fig.
S1A). More definitive evidence to im-
plicate a6Bb1 as the receptor for LM511
was obtained using transcription acti-
vator-like effector nucleases (TALENs)
to disrupt the alternative splicing site
in the a6 mRNA, which results in loss
of a6B expression (Goel et al. 2014).
TALEN-mediated depletion of a6Bb1
inhibited adhesion to LM511 without
affecting adhesion to LM111 (Fig. 1D,
right). Adhesion to LM111 was not affected because
depletion of a6Bb1 increases a6Ab1 (Goel et al. 2014),
which likely functions as a LM111 receptor. The
residual adhesion of MDA-231–a6B–TALEN cells to
LM511 at a high concentration (5 mg/mL) appears to be
mediated by a6Ab1 because it was inhibited signifi-
cantly by GoH3, an a6 inhibitory antibody (Supplemen-
tal Fig. S1B).
Figure 1. LM511 is the preferred ligand for integrin a6Bb1. (A) Relative mRNA expression
of LMa5, LMb2, LMa3, LMb3, LMb1, and LMg2 in the MES and EPTH populations of CD44+/
CD24 Src-transformed MCF10A cells and a6Ab1- and a6Bb1-expressing SUM1315 cells
was quantified by qPCR. (B) The expression of LMa5, LMg2, and actin was assessed by
immunoblotting in these cells. (C) The cells described in A were assayed for their ability to
adhere to COL 1, FN, LM111, and LM511 (1 mg/mL). (D, left) The ability of a6Bb1-expressing
SUM1315 cells to adhere within 30 min to increasing concentrations of FN, LM111, and
LM511 was determined. (Right) Control and a6B-depleted MDA-MB-231 cells were
compared for their ability to adhere to increasing concentrations of LM111 and LM511.
a6B expression was depleted using TALENs as described (Goel et al. 2014). (E) LMa5
expression was diminished in the MES population of CD44+/CD24 Src-transformed
MCF10A cells using shRNAs, and the ability of these cells to adhere to glass was assayed.
(F) Flow cytometric analysis of surface-bound LMa5 expression in EPTH and MES cells. (G)
Three primary human breast tumors (T1, T2, and T3) were dissociated and sorted by FACS
using a LMa5 Ab. Cells with low surface-bound LMa5 (P1, P3, and P4) were compared with
cells with high surface-bound LMa5 (P2, P4, and P6) for their ability to form mammospheres
(bar graph). (H) Frozen sections of human triple-negative breast cancers were stained with
a LMa5 Ab, 4C7, using either immunohistochemistry (top) or immunofluorescence
(bottom). Arrows depict individual cells with intense staining. Bar, 100 mm.
Chang et al.
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Our data suggest that LM511 is produced by breast
CSCs and that it functions as the ligand for a6Bb1 to
promote self-renewal and tumor initiation. To test this
hypothesis, we depleted LMa5 expression in MES cells
and observed a significant decrease in their adhesion to
glass (Fig. 1E). The possibility that breast CSCs produce
a LM511 matrix was substantiated by sorting the MES
cells using a LMa5 Ab. This process revealed a relatively
small population of tumor cells (;2%) that exhibited
high surface-bound LMa5 (Fig. 1F). A similar approach
was used to analyze three primary breast tumors, and we
found that each tumor contained a relatively small
population of cells with high surface-bound LMa5 (Fig.
1G). Importantly, this population has an increased ability
to form mammospheres (Fig. 1G) and expresses more of
a MES marker (vimentin) and less of an EPTH marker (E-
Cadherin) than the bulk population (Supplemental Fig.
S1C,D). Also, immunohistochemistry staining of breast
tumors identified a small number of cells that exhibited
high LMa5 expression compared with other tumor cells
(Fig. 1H).
Subsequently, we investigated the contribution of
LMa5 to self-renewal and tumor initiation more rigor-
ously. The LMa5-blocking Abs (4C7 and 8G9) reduced
the ability of MES cells to form primary mammospheres,
an effect that was synergistic in the presence of both
Abs (Fig. 2A). Depletion of LMa5 in these cells using
shRNAs resulted in a significant decrease in self-renewal,
as assessed by serial passaging ofmammo-
spheres (Fig. 2B). Orthotopic injection
of the shLMa5 cells into the mammary
fat pad resulted in a significant increase
in tumor-free survival compared with
control cells (Fig. 2C). We also made use
of a transgenic model of breast cancer in
which the Rb pathways were inactivated
in the mammary epithelium by the SV40
large T-antigen (T121) along with condi-
tional alleles of p53 and Brca1 (Kumar
et al. 2012; Goel et al. 2013). These
TgMFT121; Brca1f/f p53f/f; TgWAP-Cre
mice (referred to as TBP) develop poorly
differentiated carcinomas with a triple-
negative phenotype (Kumar et al. 2012).
We isolated a population of cells from
TBP tumors (a6high/b1high) enriched for
cells with stem cell properties (Shackleton
et al. 2006; Stingl et al. 2006), which con-
stitute a relatively small fraction of tumor
cells (Fig. 2D). This population, which ex-
presses a6B, exhibited substantially more
LMa5 expression and ability to formmam-
mospheres compared with the non-CSC
populations (Fig. 2D). The ability of this
CSC population to form mammospheres
and initiate new tumors is dependent on its
expression of LMa5 (Fig. 2E,F).
LM511/a6Bb1 promote TAZ
activation
The data provided thus far indicate that
LM511 is the preferred ligand for a6Bb1
and that it functions in this capacity to
promote self-renewal and tumor initia-
tion. Insight into the mechanism by which
LM511 promotes these functions was obtained by ana-
lyzing our RNA-seq data (Supplemental Table S1). This
analysis revealed that the MES population is enriched for
the expression of genes regulated by the Hippo transducers
TAZ and YAP (Varelas 2014) compared with the EPTH
population. The significance of this observation is sup-
ported by the report that TAZ is necessary for the function
of breast CSCs (Cordenonsi et al. 2011). We confirmed our
RNA-seq data by comparing the expression of TAZ target
genes in these populations by qPCR (Fig. 3A) and de-
termining that TAZ nuclear localization is significantly
higher in the a6Bb1-expressing (Fig. 3B) andMES cells (Fig.
3C) than in the EPTH and a6Ab1-expressing cells. In-
terestingly, YAPnuclear localization did not differ asmuch
between these populations (Fig. 3C). Also, the activity of
TEADs, the dominant transcription factors that anchor
TAZ on DNA (Varelas 2014), was significantly higher in
a6Bb1-expressing cells (SUM1315) and MES compared
with a6Ab1-expressing (SUM1315) and EPTH cells (Fig.
3D; Supplemental Fig. S1E). The importance of TAZ in
mammosphere formation and self-renewal was also con-
firmed (Fig. 3E).
More definitive evidence to implicate LM511 in reg-
ulating TAZ activity was obtained by comparing TAZ
nuclear localization and target gene expression in cells
plated on LM111 and LM511. Clearly, LM511 attach-
ment promotes TAZ activation (Fig. 3F) and TAZ target
gene expression (Fig. 3G) more robustly than LM111.
Figure 2. Autocrine LM511 is necessary for self-renewal and tumor initiation. (A)
Mammosphere cultures of MES cells were treated with LMa5-blocking antibodies (4C7
and 8G9) daily for 1 wk and quantified. (B) LMa5 expression was diminished in a6Bb1-
expressing SUM1315 cells using shRNAs, and these cells were used for serial passaging of
mammospheres. (C) Control (shGFP) and LMa5-diminished MES cells were injected into
the mammary fat pads of NSG mice, and tumor formation was assessed by palpation. The
curve comparison was done using a log rank test (P < 0.05). (D) TBP mammary tumor cells
were sorted by FACS using a6 and b1 integrin Abs. The four populations generated were
analyzed for a6B and LMa5 expression and mammosphere formation. Subsequently, LMa5
expression was diminished in the a6high/b1high population using shRNAs, and the impact on
mammosphere formation and tumor-free survival (P < 0.05) was determined. (E,F) LMa5
expression was diminished in the a6high/b1high population using shRNAs, and the impact on
mammosphere formation (E) and tumor-free survival (F) (P < 0.05) was determined.
TAZ regulates a LM511 cancer stem cell matrix
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Depletion of LMa5 expression resulted in a significant
decrease in TAZ nuclear localization and target gene
expression (Fig. 3H,I). We also validated the contribution
of a6Bb1 to TAZ activation directly by
comparing the activity of a TEAD re-
porter construct and expression of TAZ
target genes in cells in which a6B had been
deleted using TALENs (Goel et al. 2014)
to control cells (Fig. 3J,K). Importantly,
TALEN-mediated deletion of a6B also pre-
vented tumor formation upon orthotopic
injection (Fig. 3L).
The regulation of TAZ by LM511 ap-
pears to be independent of Hippo sig-
naling based on our observations that
the ability of LM511 to activate TAZ is
independent of cell confluence (data not
shown) and that knockdown of Lats1 did
not increase LMa5 expression (Fig. 3M).
Although we do not exclude the involve-
ment of Hippo signaling, our observations
are consistent with other reports of Hippo-
independent YAP/TAZ activation (e.g.,
Dupont et al. 2011).
TAZ regulates LMa5 expression
Although TAZ has been implicated in the
function of breast CSCs (Cordenonsi et al.
2011), the mechanisms involved have not
been established. Given our observation
that both TAZ target genes and LMa5 are
enriched in cells with stem-like proper-
ties, we investigated the possibility that
TAZ regulates LMa5 expression. Indeed,
we discovered that knockdown of TAZ,
but not YAP, diminished LMa5 mRNA
expression significantly (Fig. 4A,B). This
effect was also observed on LMa5 pro-
tein expression (Fig. 4A,B). These results
prompted us to pursue the possibility
that LMa5 is a TAZ target gene. We
cloned the LMa5 promoter and detected
a twofold increase in its activity in MES
cells compared with EPTH cells (Fig. 4C,
left). To establish that this activity is
dependent on TAZ, we cotransfected the
promoter construct with or without ex-
ogenous TAZ expression in HEK293
cells and observed that TAZ expression
increased promoter activity significantly
compared with vector control (Fig. 4C,
right).
TAZ does not have a DNA-binding site
and functions as a transcriptional co-
activator (Kanai et al. 2000). In silico
motif analysis of the LMa5 promoter
identified multiple TEAD-binding motifs
(Fig. 4D). The TEAD transcription fac-
tor is the predominant mediator of TAZ
function in the Hippo pathway (Varelas
2014). Chromatin immunoprecipitation
(ChIP) was used to establish binding of
TAZ to these TEAD-binding sites (Fig.
4D). To control for specificity, no TAZ
binding was detected in exons of the
LMa5 gene (Fig. 4D). Exogenous expression of TAZ in
the LMa5-low population of cells sorted from three PDX
tumors was sufficient to increase their expression of
Figure 3. LM511/a6Bb1 promotes TAZ activation. (A) Relative mRNA expression of TAZ
target genes in the MES and EPTH populations of CD44+/CD24 Src-transformed MCF10A cells
and a6Ab1- and a6Bb1-expressing SUM1315 cells was quantified by qPCR. (B) a6Ab1- and
a6Bb1-expressing SUM1315 cells were plated on a LM511 matrix, and the localization of TAZ
was assessed by immunofluorescence. (C) The same assay as in B was performed using the MES
and EPTH populations of CD44+/CD24 Src-transformed MCF10A cells, and both YAP
localization and TAZ localization were assessed. (D) TEAD transcriptional activity was assayed
in a6Ab1- and a6Bb1-expressing SUM1315 cells and parental cells by transient expression of the
8XGTIIC-luciferase reporter construct. (E) TAZ expression was diminished using shRNA in the
MES and a6Bb1-expressing SUM1315 cells, and the impact on serial mammosphere passage was
evaluated. (F) TAZ localization was assessed by immunofluorescence in confluent cultures of
SUM1315 cells on either a LM111 or LM511 matrix. (G) Expression of TAZ target genes was
quantified by qPCR in SUM1315 cells plated on either LM111 or LM511. (H,I) LMa5 expression
was diminished in SUM1315 cells, and the impact on the expression of TAZ localization (H) and
TAZ target genes (I) was determined. (J,K) Expression of integrin a6B was depleted in MDA-MB-
231 cells using a6B-specific TALENs (see Fig. 1E). These cells (Puro alone, TALENs-pool,
TALENs-C1, and TALENs-C2) were used to assay TEAD transcriptional activity (J) and expression
of TAZ target genes (K). (L) Control (Puro alone) and TALENs-pool cells were injected into the
mammary fat pads of NSG mice, and tumor formation was assessed by palpation. The curve
comparison was done using a log rank test (P < 0.05). (M) Expression of Lats1/2 was diminished in
EPTH cells using siRNAs, and mRNA expression of Lats1/2 and LMa5 was quantified by qPCR.
Bar graphs in this figure represent the average of three independent experiments, and the P-value
was determined using Student’s t-test. Bars, 100 mm.
Chang et al.
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LMa5 mRNA and ability to form mammospheres signif-
icantly (Fig. 4E,F).
The above findings infer that TAZ regulates the expres-
sion of a LM511 matrix. To examine this hypothesis, we
assessed the impact of TAZ knockdown on surface-bound
LMa5 by flow cytometry. As shown in Figure 4G, diminish-
ing TAZ significantly decreased the frequency of the small
population of cells with high surface-bound LMa5 (see Fig.
1F,G). We also found that TAZ knockdown reduced the
ability of cells to deposit a LM511matrix in culture (Fig. 4H).
In this study, we identified LM511 as the ligand for
a6Bb1 and demonstrated that LM511/a6Bb1 signaling
promotes stem cell properties by acti-
vating the Hippo transducer TAZ. The
regulation and function of YAP and
TAZ in cancer have been the focus
of intense investigation (Piccolo et al.
2013; Yu and Guan 2013). However,
aside from the report that an MT1–
MMP/b1 integrin cascade promotes
YAP/TAZ nuclear localization in skele-
tal stem cells (Tang et al. 2013), nothing
is known about ECM/integrin regulation
of YAP/TAZ in cancer. For this reason,
our discovery that breast CSCs produce
a LM511 matrix that functions to sustain
TAZ activation and stem cell properties is
a significant advancement that highlights
the importance of the ECM in regulating
Hippo effectors (Yu and Guan 2013).
Moreover, our data reveal that high
LM511 expression is a useful marker
for identifying tumor cells with stem
cell properties and that such cells can
be isolated by flow cytometry using
LMa5 Abs.
The second major conclusion of this
study is that LMa5 is a TAZ target gene
and that TAZ regulates the formation
of a LM511 matrix. This conclusion is
significant because it provides insight
into the mechanism by which TAZ con-
tributes to the function of CSCs. Indeed,
our finding that TAZ contributes to the
regulation of LMa5 transcription impli-
cates the ECM as a critical effector of
TAZ-mediated functions. Our data also
indicate that breast CSCs generate a
LM511 matrix using a positive feedback
loop that involves LM511/a6Bb1-medi-
ated activation of TAZ and TAZ-medi-
ated regulation of LM511. These findings
imply that breast CSCs generate their own
matrix niche that functions to maintain
stemness by sustaining TAZ activation.
Materials and methods
Cells
ER-SRC-transformed MCF-10A cells were provided
byDr. Kevin Struhl (HarvardMedical School, Boston,
MA). Isolation of the CD44+/CD24 population from
these Src-transformed MCF10A cells and character-
ization of distinct EPTH and MES populations have
been described (Goel et al. 2014). The generation of
SUM1315 cells that express either a6Ab1 or a6Bb1, the use of TALENs to
target the splicing site in the a6 subunit, and the generation of a6B-depleted
cells have also been described (Goel et al. 2014). HEK293 cells were
purchased from American Type Culture Collection. Flow cytometry was
used to analyze surface expression of the a6 integrin, CD44, and CD24.
RNA-seq analysis
RNA was extracted from the indicated cells and sent to Beijing Genomics
Institute (BGI) for quantification, sequencing, and analysis. Sequencing was
performed on the single end of themRNA fragment with a reading length of
50 base pairs (bp). Each sample had a sequencing depth of 5 million.
Figure 4. TAZ regulates LMa5 expression. (A) Expression of either TAZ or YAP was
diminished in MES cells, and the impact on LMa5 mRNA expression was quantified by
qPCR. LMa5 protein expression in TAZ-depleted cells was also evaluated by immunoblotting.
(B) TAZ expression was diminished in SUM1315 cells, and the impact on LMa5 mRNA and
protein expression was determined. (C, left) A luciferase construct containing the LMa5
promoter was generated and used to assay LMa5 transcriptional activity in the MES and EPTH
cells. (Right) LMa5 promoter activity was assayed using the same reporter construct in control
and TAZ-expressing HEK293 cells. (D, top) Schematic of the LMa5 promoter indicating the
location of the putative TEAD-binding sites. (Bottom) Binding of TAZ to the LMa5 promoter
was assayed by ChIP. (E,F) Cells with low surface-bound LMa5 (from PDX breast tumors) were
isolated and infected with lentiviral particles expressing TAZ. (E) Expression of TAZ and LMa5
mRNA expression was quantified by qPCR. (F) These transfected cells were also assayed for
their ability to form mammospheres. (G) Surface-bound LMa5 was quantified by flow
cytometry in the EPTH cells transfected with empty vector or TAZ shRNAs. (H) MES cells
were cultured for 4 d and detached using EDTA (25 mM), and the exposed matrix was analyzed
for LMa5 expression by immunofluorescence.
TAZ regulates a LM511 cancer stem cell matrix
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Additional details about the materials and methods are provided in the
Supplemental Material.
Accession numbers
The accession number for the REN-seq data is SRX767003. The project
accession number for the REN-seq data is PRJNA268321.
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